Philippe Camus, M.D.

Dijon, France

Back to drug

The Drug-Induced Respiratory Disease Website

XVI.i

Hemoptysis

(Fr: hémoptysie isolée). Lone hemoptysis. Hemoptysis presumed to be drug-induced may disclose an underlying airway or pulmonary benign or malignant condition. Hemoptysis is a classic, though inconsistent manifestation of underlying diffuse alveolar hemorrhage or DAH (see under IIIa). Certain drugs do increase the risk of post-procedural (e.g. TBLB, maybe also cryobiopsy) bleeding and need to be withdrawn prior to the procedure

Publications

Goto K, Endo M, Kusumoto M, Yamamoto N, Ohe Y, Shimizu A, Fukuoka M

Bevacizumab for non-small-cell lung cancer: A nested case control study of risk factors for hemoptysis.

Cancer science 2016 Dec;107;1837-1842 — 2016 Dec — 1837-1842

Okamoto K, Okamoto I, Miyazaki M, Tanaka K, Kaneda H, Nakagawa K

Bronchoscopic findings for bevacizumab-related pulmonary hemorrhage in advanced non-small cell lung cancer.

Investigational new drugs 2013 Oct;31;1364-6 — 2013 Oct — 1364-6

Reck M, Barlesi F, Crinò L, Henschke CI, Isla D, Stiebeler S, Spigel DR

Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts.

Annals of oncology : official journal of the European Society for Medical Oncology 2012 May;23;1111-20 — 2012 May — 1111-20

Hapani S, Sher A, Chu D, Wu S

Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis.

Oncology 2010;79;27-38 — 2010 — 27-38

Crinò L, Dansin E, Garrido P, Griesinger F, Laskin J, Pavlakis N, Stroiakovski D, Thatcher N, Tsai CM, Wu YL, Zhou C

Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study.

The Lancet. Oncology 2010 Aug;11;733-40 — 2010 Aug — 733-40

Cho YJ, Murgu SD, Colt HG

Bronchoscopy for bevacizumab-related hemoptysis.

Lung cancer (Amsterdam, Netherlands) 2007 Jun;56;465-8 — 2007 Jun — 465-8

Herbst RS, Sandler AB

Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab?

The oncologist 2004;9 Suppl 1;19-26 — 2004 — 19-26

Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004 Jun 01;22;2184-91 — 2004 Jun 01 — 2184-91